People weaning themselves from painkillers may soon get a helping hand via a zap in the brain. The FDA says the snappy-sounding Neuro-Stim System Bridge, which costs between $600 and $800, can now be marketed as a way to treat opioid withdrawal.
It’s a seemingly simple device, which attaches to the skin behind the ear and uses a chip to stimulate part of the brain that usually processes pain information such as that created by withdrawal. While it’s been used in clinics to treat withdrawal in the past, until now it was approved by the FDA only for treatment of acute and chronic pain—not symptoms related to halting opioid consumption.
As Stat points out, the evidence supporting the device’s efficacy is slim: the FDA cites just a single study including 73 patients. But that series of experiments did show that 88 percent of them “successfully transitioned” away from opioids after using the device for five days. And at any rate, it’s a start against an overpowering scourge.
More solutions may be forthcoming. As we’ve reported, devices like the Bridge are just one of a series of promising approaches to beating addictive drugs—and in the meantime, the quest for painkillers that aren’t addictive continues, too.
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.